Privi Speciality Chemicals (PRIVISCL) Q3 24/25 earnings summary

Executive summary

• Achieved strong growth in Q3 and 9M FY25, with 33% volume growth, 16% revenue growth, 29% EBITDA growth, and 90% PAT growth YoY, despite global headwinds and a planned shutdown for capacity enhancement.

• Focused on capacity expansion, process improvements, and sustainability initiatives, including increased green power usage, improved ESG ratings, and receipt of the Trishul Award for export excellence.

• Commercial production commenced at the Givaudan JV, with ramp-up on track for complex ingredient manufacturing.

• Strategic focus on product mix, operational efficiency, and new product development to drive future growth.

• Board approved unaudited financial results for Q3 and 9M FY25 and reconstituted committees following the resignation of an Independent Director.

Financial highlights

• Q3 FY25 consolidated revenue at Rs. 49,087.12 lakhs, up over 20% YoY; EBITDA at Rs. 150 crores, up 20%; PAT at Rs. 4,447.45 lakhs, up from Rs. 2,877.25 lakhs YoY.

• 9M FY25 revenue at Rs. 1,493 crores, up 16% YoY; EBITDA at Rs. 327 crores, up 29%; PAT at Rs. 120.77 crores, up 90% YoY.

• EBITDA margin stable at 23.3% in Q3 FY25; PAT margin improved to 9.0% from 7.0% YoY.

• Gross profit margin reached close to 52%, with a temporary increase in other expenses due to one-time air freight costs, which were recovered from customers.

• EPS for 9M FY25 at Rs 30.84, up from Rs 16.27 YoY.

Outlook and guidance

• Confident of maintaining at least 20% revenue growth for FY26, supported by a strong order book and contracted business.

• EBITDA margins expected to remain at current levels or improve, with 70% of business already booked for the year.

• Price increases of 7-10% for various products to be reflected from Q4.

• Volume growth expected around 15%, with revenue growth at 20%.

• Comprehensive growth strategy includes improving product mix, operational efficiencies, and capitalizing on emerging market trends.